Toward Ovarian Cancer Screening with Protein Biomarkers Using Dried, Self-sampled Cervico-vaginal Fluid

Overview

Journal iScience

Publisher Cell Press

Date 2024 Feb 14

PMID 38352226

Authors

Julia Hedlund Lindberg

Anna Widgren

Emma Ivansson

Inger Gustavsson

Karin Stalberg

Ulf Gyllensten

Karin Sundfeldt

Jonas Bergquist

Stefan Enroth

Affiliations

Soon will be listed here.

Abstract

Early detection is key for increased survival in ovarian cancer, but no general screening program exists today due to lack of biomarkers and overall cost versus benefit over traditional clinical methods. Here, we used dried cervico-vaginal fluid (CVF) as sampling matrix coupled with mass spectrometry for detection of protein biomarkers. We find that self-collected CVF on paper cards yields robust results and is suitable for high-throughput proteomics. Artificial intelligence-based methods were used to identify an 11-protein panel that separates cases from controls. In validation data, the panel achieved a sensitivity of 0.97 (95% CI 0.91-1.00) at a specificity of 0.67 (0.40-0.87). Analyses of samples collected prior to development of symptoms indicate that the panel is informative also of future risk of disease. Dried CVF is used in cervical cancer screening, and our results opens the possibility for a screening program also for ovarian cancer, based on self-collected CVF samples.

Citing Articles

Novel diagnostics for improved treatment of gynecological cancer.

Gyllensten U Ups J Med Sci. 2025; 130.

PMID: 39981201 PMC: 11836773. DOI: 10.48101/ujms.v130.12111.

References

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Soletormos G, Duffy M, Othman Abu Hassan S, Verheijen R, Tholander B, Bast Jr R . Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer. 2015; 26(1):43-51. PMC: 4679342. DOI: 10.1097/IGC.0000000000000586. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Bast Jr R, Klug T, St John E, Jenison E, Niloff J, Lazarus H . A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309(15):883-7. DOI: 10.1056/NEJM198310133091503. View

Gustavsson I, Aarnio R, Myrnas M, Hedlund-Lindberg J, Taku O, Meiring T . Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening. Virol J. 2019; 16(1):107. PMC: 6704622. DOI: 10.1186/s12985-019-1216-7. View

Anttila M, Kosma V, Ji H, Puolakka J, Juhola M, Saarikoski S . Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol. 1998; 16(8):2591-600. DOI: 10.1200/JCO.1998.16.8.2591. View

Shih I, Wang Y, Wang T . The Origin of Ovarian Cancer Species and Precancerous Landscape. Am J Pathol. 2020; 191(1):26-39. PMC: 7786078. DOI: 10.1016/j.ajpath.2020.09.006. View

Chen Q, Zhang Z, Wang S, Lang J . Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer. Onco Targets Ther. 2020; 12:11517-11530. PMC: 6938177. DOI: 10.2147/OTT.S227156. View

10.

Enroth S, Berggrund M, Lycke M, Broberg J, Lundberg M, Assarsson E . High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. Commun Biol. 2019; 2:221. PMC: 6586828. DOI: 10.1038/s42003-019-0464-9. View

11.

Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Sanner K, Wikstrom I . Randomised study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel. Int J Cancer. 2018; 144(1):89-97. DOI: 10.1002/ijc.31637. View

12.

Lycke M, Kristjansdottir B, Sundfeldt K . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1):159-165. DOI: 10.1016/j.ygyno.2018.08.025. View

13.

Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand A, Sanner K . Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer. 2018; 118(6):896-904. PMC: 5886121. DOI: 10.1038/bjc.2017.485. View

14.

Brown P, Palmer C . The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009; 6(7):e1000114. PMC: 2711307. DOI: 10.1371/journal.pmed.1000114. View

15.

Albert M, Bartlett J, Johnston R, Schacter B, Watson P . Biobank bootstrapping: is biobank sustainability possible through cost recovery?. Biopreserv Biobank. 2014; 12(6):374-80. DOI: 10.1089/bio.2014.0051. View

16.

Jacobs I, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi J . Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2015; 387(10022):945-956. PMC: 4779792. DOI: 10.1016/S0140-6736(15)01224-6. View

17.

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C . Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397(10290):2182-2193. PMC: 8192829. DOI: 10.1016/S0140-6736(21)00731-5. View

18.

Gutierrez A, Hedlund Lindberg J, Shevchenko G, Gustavsson I, Bergquist J, Gyllensten U . Identification of Candidate Protein Biomarkers for CIN2+ Lesions from Self-Sampled, Dried Cervico-Vaginal Fluid Using LC-MS/MS. Cancers (Basel). 2021; 13(11). PMC: 8198222. DOI: 10.3390/cancers13112592. View

19.

Gyllensten U, Hedlund-Lindberg J, Svensson J, Manninen J, Ost T, Ramsell J . Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. Cancers (Basel). 2022; 14(7). PMC: 8997113. DOI: 10.3390/cancers14071757. View

20.

Karlsen M, Sandhu N, Hogdall C, Christensen I, Nedergaard L, Lundvall L . Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012; 127(2):379-83. DOI: 10.1016/j.ygyno.2012.07.106. View